ISSN ONLINE: 2558-815X
ISSN PRINT: 1584-9244
ISSN-L: 1584-9244

Maximum Benefit From the Addition of Ezetimibe to Statin Therapy Is Seen in Patients With Diabetes

211 views

The IMPROVE-IT trial showed that Ezetimibe was the first non-statin agent which reduced major cardiovascular events in combination with a statin. 18,144 patients with an LDL-C level of 50 to 125 mg/dL were randomized to receive ezetimibe plus simvastatin 40 mg or placebo plus simvastatin 40 mg (P/S) to compare benefits in those with and without diabetes mellitus. Adding ezetimibe to statin therapy provided maximum clinical benefit for patients with DM or those at a high cardiovascular risk.

(http://www.practiceupdate.com/journalscan/42759/1/2?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_cardio&elsca4=cardiology&elsca5=newsletter&rid=MzAxMjc1MjcwODY5S0&lid=10332481)

Share.

About Author

Comments are closed.